Posicionamiento de la Sociedad Española de Reumatología (SER) y la Sociedad Española de Investigación Ósea y Metabolismo Mineral (SEIOMM) respecto a romosozumab

Castañeda, Santos; Gómez-Alonso, Carlos; Graña, Jenaro; Guañabens, Núria; Muñoz-Torres, Manuel; Peris, Pilar; Naves, Manuel; Álvaro-Gracia, José M.
Reumatol. clín. (Barc.) ; 18(7): 383-386, Ago.- Sep. 2022.
Artículo en Español | IBECS (España) | ID: ibc-207307

Documentos relacionados

  1. [A breakthrough in the management of postmenopausal osteoporosis with very high fracture risk : romosozumab (Evenity®), a humanized monoclonal anti-sclerostin antibody].
  2. Romosozumab and antiresorptive treatment: the importance of treatment sequence.
  3. Clinical Impact on Dental Implant Survival in Patients Taking Antiresorptive Medications: A Systematic Review and Meta-Analysis.
  4. Pre-treatment bone turnover does not influence the level of the response to alendronate in postmenopausal osteoporosis at the bone tissue level.
  5. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
  6. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
  7. Updated trabecular bone score accounting for the soft tissue thickness (TBS<sub>TT</sub>) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis.
  8. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.
  9. Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty.
  10. Long-term effects of denosumab on bone mineral density and turnover markers in patients undergoing hemodialysis.